MX2009006457A - Metodos y composiciones para el tratamiento de enfermedades de fibrosis relacionadas con interleucina-4 o interleucina-13. - Google Patents

Metodos y composiciones para el tratamiento de enfermedades de fibrosis relacionadas con interleucina-4 o interleucina-13.

Info

Publication number
MX2009006457A
MX2009006457A MX2009006457A MX2009006457A MX2009006457A MX 2009006457 A MX2009006457 A MX 2009006457A MX 2009006457 A MX2009006457 A MX 2009006457A MX 2009006457 A MX2009006457 A MX 2009006457A MX 2009006457 A MX2009006457 A MX 2009006457A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating
pathologies
fibrosis
Prior art date
Application number
MX2009006457A
Other languages
English (en)
Inventor
Lynne A Murray
Original Assignee
Centocor Ortho Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Ortho Biotech Inc filed Critical Centocor Ortho Biotech Inc
Publication of MX2009006457A publication Critical patent/MX2009006457A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con composiciones y métodos para tratar una condición o patología relacionada con fibrosis relacionada con IL-4 o IL-13, incluyendo composiciones, formulaciones, métodos y dispositivos terapéuticos.
MX2009006457A 2006-12-15 2007-12-13 Metodos y composiciones para el tratamiento de enfermedades de fibrosis relacionadas con interleucina-4 o interleucina-13. MX2009006457A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87010506P 2006-12-15 2006-12-15
PCT/US2007/087346 WO2008076784A2 (en) 2006-12-15 2007-12-13 Methods and compositions for treating il-4 or il-13 related fibrosis related pathologies

Publications (1)

Publication Number Publication Date
MX2009006457A true MX2009006457A (es) 2009-08-25

Family

ID=39536976

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006457A MX2009006457A (es) 2006-12-15 2007-12-13 Metodos y composiciones para el tratamiento de enfermedades de fibrosis relacionadas con interleucina-4 o interleucina-13.

Country Status (13)

Country Link
US (1) US20100008914A1 (es)
EP (1) EP2125037A2 (es)
JP (1) JP2010513301A (es)
KR (1) KR20090101924A (es)
CN (1) CN101646465A (es)
AU (1) AU2007334022A1 (es)
BR (1) BRPI0721170A2 (es)
CA (1) CA2672878A1 (es)
EA (1) EA200970588A1 (es)
IL (1) IL199347A0 (es)
MX (1) MX2009006457A (es)
WO (1) WO2008076784A2 (es)
ZA (1) ZA200904921B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
AR085911A1 (es) * 2011-03-16 2013-11-06 Sanofi Sa Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
US10232039B2 (en) 2011-04-12 2019-03-19 Duke University Compositions and methods for the treatment of tissue fibrosis
CN111494625B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
EP1552462B1 (en) * 2002-06-14 2011-03-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods of treating and preventing colitis involving il-13 and nk-t cells

Also Published As

Publication number Publication date
CA2672878A1 (en) 2008-06-26
BRPI0721170A2 (pt) 2014-03-18
AU2007334022A1 (en) 2008-06-26
WO2008076784A3 (en) 2008-10-23
JP2010513301A (ja) 2010-04-30
CN101646465A (zh) 2010-02-10
ZA200904921B (en) 2010-09-29
KR20090101924A (ko) 2009-09-29
US20100008914A1 (en) 2010-01-14
EP2125037A2 (en) 2009-12-02
EA200970588A1 (ru) 2009-12-30
WO2008076784A2 (en) 2008-06-26
IL199347A0 (en) 2010-03-28

Similar Documents

Publication Publication Date Title
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
IL277322B (en) Compositions and methods for treating collagen-mediated diseases
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
SG170024A1 (en) Imidazole-based compounds, compositions comprising them and methods of their use
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
HK1123000A1 (en) Compositions and methods for the treatment and prevention of fibrotic, inflammatory and neovascularization conditions
HK1166983A1 (zh) 包含用於治療疾病或紊亂的化合物的固體形式，其組合物，及其用途
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
MX286273B (es) Composiciones y metodos para inhibicion de la via jak.
MY161415A (en) A homeopathic formulation
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2006105538A3 (en) Methods and compositions for treating il-21 related pathologies
ZA200901132B (en) Human GLP-1 mimetibodies, compositions, methods and uses
IN2012DN02471A (es)
TW200716088A (en) Formulations and methods for treating amyloidosis
ZA200800448B (en) Methods and compositions for the prevention and treatment of inflammatory disease
MX2009009190A (es) Compuestos heterociclicos, composiciones que los comprenden y metodos que los emplean.
EP1996218A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
IL191537A0 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2005044200A3 (en) Methods and compositions for treating mcp-1 related pathologies
MX2009006457A (es) Metodos y composiciones para el tratamiento de enfermedades de fibrosis relacionadas con interleucina-4 o interleucina-13.
WO2008022807A3 (en) Lipoxin a4 analogs for the treatment and prevention of intestinal fibrosis
UA94737C2 (ru) Соединения на основе имидазола, композиция, которая их содержит, и их применение
UA97289C2 (ru) Соединения и их композиция как модуляторы gpr119 активности

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal